2021 World Conference on Lung Cancer (Posters)-FP12. Obesity is Associated With Greater Overall Survival in Patients With Metastatic NSCLC Receiving First-Line Pembrolizumab

FP12. Obesity is Associated With Greater Overall Survival in Patients With Metastatic NSCLC Receiving First-Line Pembrolizumab

Back to course

Video Transcription

Video Summary

This presentation discusses a study investigating the association between obesity and overall survival in metastatic non-small-cell lung cancer patients receiving first-line Pembrolizumab therapy. The study found that obese patients had significantly longer overall survival compared to non-obese patients. Possible explanations for this association include a dysfunctional immune state in obese patients, which may make them more responsive to Pembrolizumab, or the physiological advantage of having a larger reserve that slows the progression of cachexia. However, the study acknowledges that further research is needed to determine whether this association is true or due to other factors. Additionally, alternative measures of obesity and body composition should be explored.

Asset Subtitle

Findlay David Thomson

Meta Tag

Speaker Findlay David Thomson

Topic Predictive Tumor Based Assays/ Biomarkers/ Pathology

Keywords

obesity

overall survival

metastatic non-small-cell lung cancer

Pembrolizumab therapy

immune state